Navigation Links
Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010

Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on... -- HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News Click to view news release full screen  

Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010


HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that it will participate in the Rodman and Renshaw Annual Global Investment Conference on Tuesday, September 14th, 2010.

Conference: Rodman and Renshaw Annual Global Investment Conference Date: Tuesday, September 14th 2010 Time: 4:30 - 4:55 PM ET Location: Kennedy Salon (4th FL), New York Palace Hotel New York, New York

Mr. Ren Hu, Vice President of Finance of Weikang, will present the Company's operations, business strategy, financial results, and outlook as well as answer investors' questions during the presentation and at one-on-one meetings.

Investors interested in attending the event should contact their Rodman and Renshaw sales representative. For more information about the conference, please visit .

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit .

Safe Harbor Statement

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For further information, please contact: Company contact: Ren Hu, VP of Finance Weikang Bio-Technology Group Co., Inc. US Cell: +1-201-887-0415 Email: Investors Relation contacts: John Marco, Partner, Elite IR Tel: +1-310-819-2948 Email: Leslie J. Richardson, Partner, Elite IR Tel: +852-3183-0283 Email: Leslie.richardson

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
2. Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference
3. Lexicon to Present at Morgan Stanley Global Healthcare Conference
4. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
5. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
6. The Female Health Company to Present at Rodman & Renshaws Annual Global Investment Conference on Wednesday, September 15, 2010
7. Sequenom to Present at Two Financial Conferences in September
8. Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups
9. Marrone Bio Innovations to Present Invasive Mussel Control Solution
10. MO BIO Laboratories, Inc. DNA Isolation Products Used to Analyze Microbes Present in Deepwater Horizon Oil Plume
11. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... companion diagnostics is one of the major ... pharmaceutical companies and diagnostic manufacturers working together ... . --> ... global cancer biomarkers market spread across 89 ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... , November 26, 2015 ... Global Biobanking Market 2016 - 2020 report analyzes ... maintaining integrity and quality in long-term samples, minimizing ... long-term cost-effectiveness. Automation minimizes manual errors such as ... technical efficiency. Further, it plays a vital role ...
Breaking Biology Technology:
(Date:11/26/2015)... Research and Markets ( ) has announced the ... and Patent Infringement Risk Analysis" report to their ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/19/2015)... Calif. , Nov. 19, 2015  Based on ... Frost & Sullivan recognizes BIO-key with the 2015 Global ... Each year, Frost & Sullivan presents this award to ... line catering to the needs of the market it ... product line meets and expands on customer base demands, ...
Breaking Biology News(10 mins):